On Friday, Universal Health Services, Inc. (NYSE:UHS)’s shares inclined 2.68% to $145.23.
Universal Health Services, Inc. (UHS) declared that its Board of Directors voted to pay a cash dividend of $0.10 per share on September 15, 2015 to shareholders of record as of September 1, 2015.
Universal Health Services, Inc. is one of the nation’s largest hospital companies, operating, through its auxiliaries, behavioral health facilities, acute care hospitals, and ambulatory centers throughout the United States, Puerto Rico, the United Kingdom and the U.S. Virgin Islands.
Universal Health Services, Inc., through its auxiliaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The company’s hospitals offer various services, counting general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and/or behavioral health services.
Esperion Therapeutics Inc (NASDAQ:ESPR))’s shares dropped -3.50% to $62.00.
Esperion Therapeutics, Inc. (ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, recently declared it will host a conference call and webcast to provide program updates and financial results for the second quarter 2015. The conference call and webcast will take place on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time.
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products comprise ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, in addition to to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies.
At the end of Friday’s trade, Freescale Semiconductor Ltd (NYSE:FSL)‘s shares dipped -0.40% to $39.87.
Freescale Semiconductor (FSL) is planned to present at the Oppenheimer 18th Annual Technology, Internet & Communications Conference. Mitch Haws, vice president, investor relations, will present for the company. The conference will also be webcast and made accessible at investors.freescale.com.
Oppenheimer 18th Annual Technology, Internet & Communications Conference
Date: Tuesday, August 11, 2015
Time: 9:05 a.m. Eastern Time
Place: Four Seasons Hotel, Boston, MA
Freescale Semiconductor, Ltd. provides embedded processors worldwide. The company’s products comprise microcontrollers, ranging from 8-bit products to higher performance 16-bit and 32-bit products with on-board flash memory, which provide the digital logic or intelligence for electronic applications and controlling electronic equipment or analyzing sensor inputs; single-and multi-core microprocessors; and applications processors with embedded memory, and special purpose hardware and software for multimedia applications.
Biomed Realty Trust Inc (NYSE:BMR), ended its Friday’s trading session with 1.03% gain, and closed at $21.54.
BioMed Realty Trust, Inc. (BMR), investing in the highest quality institutional real estate to meet growing demand across the life science industry, stated funds from operations (FFO) and core FFO (CFFO) per diluted share of $0.58 for the second quarter ended June 30, 2015, driven by the company’s strong leasing, development deliveries, and investment acumen over the past four quarters.
The company’s unique platform, anchored by a deep team of life science real estate professionals, delivered a new record for gross leasing in the quarter with 1.3 million square feet led by new leases with Eli Lilly and Alnylam Pharmaceuticals in Cambridge, Massachusetts, Regeneron Pharmaceuticals in New York, and Illumina in Cambridge, United Kingdom, in addition to leases to top tier research institutions Duke University and Wake Forest University. Total gross leasing in the second quarter resulted in about 218,400 square feet of positive net absorption in the operating portfolio and an additional 370,300 square feet of absorption across the company’s development portfolio.
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry. The company owns or has interests in 72 properties, representing 119 buildings with about 11.0 million rentable square feet. Its properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania, and New York/New Jersey. The company qualifies as a REIT for federal income tax purposes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
